US4844119A
(en)
*
|
1988-11-21 |
1989-07-04 |
Allied-Signal Inc. |
Integrated three-way and isolation solenoid valve
|
ATE311895T1
(de)
*
|
1992-05-26 |
2005-12-15 |
Immunex Corp |
Neue zytokine die cd30 binden
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US20030040467A1
(en)
*
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US6936439B2
(en)
*
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US7070771B1
(en)
|
1996-12-09 |
2006-07-04 |
Regents Of The University Of California |
Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
|
CA2312188C
(en)
|
1997-12-08 |
2010-06-29 |
Lexigen Pharmaceuticals Corp. |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
JP2002517181A
(ja)
*
|
1998-02-06 |
2002-06-18 |
キュラサイト・アクチェンゲゼルシャフト |
細胞の活性化を調節するために提供される核酸
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
US7001999B1
(en)
*
|
1998-04-15 |
2006-02-21 |
Ludwig Institute For Cancer Research |
Tumor associated nucleic acids and uses therefor
|
BR9909583A
(pt)
*
|
1998-04-15 |
2002-01-15 |
Lexigen Pharm Corp |
Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
|
JP2002511266A
(ja)
*
|
1998-04-15 |
2002-04-16 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
腫瘍関連核酸及びその使用
|
US6245525B1
(en)
|
1998-07-27 |
2001-06-12 |
Ludwig Institute For Cancer Research |
Tumor associated nucleic acids and uses therefor
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
DE69934425T2
(de)
*
|
1998-10-23 |
2007-09-27 |
Amgen Inc., Thousand Oaks |
Thrombopoietin substitute
|
US7304150B1
(en)
*
|
1998-10-23 |
2007-12-04 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
US7488590B2
(en)
*
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
CZ20014123A3
(cs)
*
|
1999-05-19 |
2002-06-12 |
Lexigen Pharmaceuticals Corp. |
Exprese a export interferonů-alfa jako Fc fúzních proteinů
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
KR20010085996A
(ko)
*
|
1999-09-03 |
2001-09-07 |
스티븐 엠. 오드레 |
암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
|
US6808902B1
(en)
*
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
AU2154401A
(en)
|
1999-11-12 |
2001-05-30 |
Merck Patent Gmbh |
Erythropoietin forms with improved properties
|
JP2003520579A
(ja)
*
|
1999-12-08 |
2003-07-08 |
アムジェン インコーポレイテッド |
インターフェロン様分子およびその使用
|
DK1252192T3
(da)
|
2000-02-11 |
2006-11-20 |
Merck Patent Gmbh |
Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
|
US20020041864A1
(en)
*
|
2000-04-25 |
2002-04-11 |
Immunex Corporation |
Method for treatment of tumors using photodynamic therapy
|
EP1278778A2
(en)
*
|
2000-05-03 |
2003-01-29 |
Amgen Inc., |
Modified peptides, comprising an fc domain, as therapeutic agents
|
BR0112111A
(pt)
*
|
2000-06-29 |
2003-05-06 |
Merck Patent Gmbh |
Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
|
US6652854B2
(en)
*
|
2000-08-08 |
2003-11-25 |
Immunex Corporation |
Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
|
US9539348B2
(en)
*
|
2000-08-18 |
2017-01-10 |
East Carolina University |
Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
|
EP1328545B1
(en)
*
|
2000-10-18 |
2011-06-22 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Human gene critical to fertility
|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
US7090843B1
(en)
*
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
AU2002249521B2
(en)
*
|
2001-01-16 |
2007-06-21 |
Serono Genetics Institute S.A. |
Discriminative nucleic acid analysis using clone sequence signatures
|
MXPA03008031A
(es)
*
|
2001-03-07 |
2003-12-04 |
Merck Patent Gmbh |
Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
|
WO2002079415A2
(en)
*
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
DK1383785T3
(da)
*
|
2001-05-03 |
2011-05-23 |
Merck Patent Gmbh |
Rekombinant tumorspecifikt antistof og anvendelse deraf
|
CA2451138A1
(en)
*
|
2001-06-22 |
2003-01-03 |
Daiichi Suntory Pharma Co., Ltd. |
Remedies for eosinophilic diseases
|
WO2003009863A1
(en)
*
|
2001-07-26 |
2003-02-06 |
Genset S.A. |
Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
|
US7270960B2
(en)
*
|
2001-08-29 |
2007-09-18 |
Pacific Northwest Research Institute |
Diagnosis of ovarian carcinomas
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7332474B2
(en)
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
AU2002357784B2
(en)
|
2001-12-04 |
2008-07-31 |
Merck Patent Gmbh |
Immunocytokines with modulated selectivity
|
US7786282B2
(en)
|
2001-12-06 |
2010-08-31 |
The Regents Of The University Of California |
Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
|
KR100668538B1
(ko)
*
|
2002-01-09 |
2007-01-16 |
메다렉스, 인코포레이티드 |
Cd30에 대한 인간 모노클로날 항체
|
PL376536A1
(pl)
|
2002-08-28 |
2006-01-09 |
Immunex Corporation |
Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
|
JP4494977B2
(ja)
*
|
2002-12-17 |
2010-06-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
|
US20050037947A1
(en)
*
|
2003-05-06 |
2005-02-17 |
Bitonti Alan J. |
Inhibition of drug binding to serum albumin
|
ATE497783T1
(de)
*
|
2003-05-06 |
2011-02-15 |
Syntonix Pharmaceuticals Inc |
Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
TWI353991B
(en)
*
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US20050009110A1
(en)
*
|
2003-07-08 |
2005-01-13 |
Xiao-Jia Chang |
Methods of producing antibodies for diagnostics and therapeutics
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
BRPI0418286A
(pt)
|
2003-12-30 |
2007-05-02 |
Merck Patent Gmbh |
proteìnas de fusão de il-7
|
KR20060124656A
(ko)
*
|
2003-12-31 |
2006-12-05 |
메르크 파텐트 게엠베하 |
개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질
|
AU2005203962C1
(en)
*
|
2004-01-05 |
2012-11-08 |
Antisoma Research Limited |
Interleukin-12 targeted to oncofoetal fibronectin
|
CN1926237A
(zh)
*
|
2004-01-28 |
2007-03-07 |
森托尼克斯制药有限公司 |
用于治疗不育症的异二聚体促卵泡激素-Fc(FSH-Fc)融合蛋白
|
AU2004317159B2
(en)
|
2004-02-12 |
2010-12-23 |
The United States Of America, As Represented By Secretary, Department Of Health And Human Services |
Therapeutic administration of the scrambled anti-angiogenic peptide C16Y
|
US7632924B2
(en)
|
2004-06-18 |
2009-12-15 |
Ambrx, Inc. |
Antigen-binding polypeptides and their uses
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
MX2007000216A
(es)
*
|
2004-07-08 |
2007-03-15 |
Amgen Inc |
Peptidos terapeuticos.
|
WO2006016276A2
(en)
|
2004-08-03 |
2006-02-16 |
Innate Pharma S.A. |
Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
|
DK1797127T3
(da)
*
|
2004-09-24 |
2017-10-02 |
Amgen Inc |
Modificerede Fc-molekyler
|
KR20070083899A
(ko)
*
|
2004-10-01 |
2007-08-24 |
메다렉스, 인코포레이티드 |
Cd30 양성 림프종의 치료 방법
|
KR20070085886A
(ko)
*
|
2004-12-09 |
2007-08-27 |
메르크 파텐트 게엠베하 |
감소된 면역원성의 il-7 변이체
|
BRPI0607203A2
(pt)
|
2005-02-18 |
2009-08-25 |
Medarex Inc |
anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
|
WO2006116246A2
(en)
*
|
2005-04-25 |
2006-11-02 |
Medarex, Inc. |
Method of treating cd30 positive lymphomas
|
CN101198870A
(zh)
*
|
2005-06-17 |
2008-06-11 |
皇家飞利浦电子股份有限公司 |
精密磁性生物传感器
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
TW200722436A
(en)
*
|
2005-10-21 |
2007-06-16 |
Hoffmann La Roche |
A peptide-immunoglobulin-conjugate
|
US20090175886A1
(en)
*
|
2006-01-17 |
2009-07-09 |
Medarex, Inc. |
Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
|
WO2007087428A2
(en)
*
|
2006-01-25 |
2007-08-02 |
Amgen Inc. |
Thrombopoietic compounds
|
JO3324B1
(ar)
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
US7981425B2
(en)
*
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
JO2913B1
(en)
*
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
AU2010238858A1
(en)
*
|
2009-04-22 |
2011-12-08 |
Merck Patent Gmbh |
Antibody fusion proteins with modified FcRn binding sites
|
EP2464377B1
(en)
|
2009-08-14 |
2016-07-27 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
AU2011274414B2
(en)
|
2010-07-09 |
2016-10-06 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptides and methods of use thereof
|
WO2012006623A1
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Systems for factor viii processing and methods thereof
|
CA2842323A1
(en)
|
2011-07-18 |
2013-01-24 |
Arts Biologics A/S |
Long acting biologically active luteinizing hormone (lh) compound
|
EP3348575A1
(en)
|
2011-08-16 |
2018-07-18 |
Emory University |
Jaml specific binding agents, antibodies, and uses related thereto
|
ES2942483T3
(es)
|
2011-10-05 |
2023-06-01 |
Oned Mat Inc |
Materiales activos de nanoestructuras de silicio para baterías de iones de litio y procesos, composiciones, componentes y dispositivos relacionados con los mismos
|
US9360414B2
(en)
*
|
2011-10-14 |
2016-06-07 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Light refraction imaging to measure liquid volume
|
KR20140100543A
(ko)
|
2011-11-29 |
2014-08-14 |
뉴로페이지 파마슈티컬즈, 인크. |
박테리오파아지 유전자 3 단백질 조성물 및 아밀로이드 결합제로서의 용도
|
ES2725569T3
(es)
*
|
2012-02-10 |
2019-09-24 |
Seattle Genetics Inc |
Diagnóstico y tratamiento de cánceres que expresan CD30
|
HUE039118T2
(hu)
|
2012-04-27 |
2018-12-28 |
Novo Nordisk As |
Humán cd30 ligandum antigén kötõ proteinek
|
EP2846822A2
(en)
|
2012-05-11 |
2015-03-18 |
Prorec Bio AB |
Method for diagnosis and treatment of prolactin associated disorders
|
GB201216649D0
(en)
*
|
2012-09-18 |
2012-10-31 |
Univ Birmingham |
Agents and methods
|
ES2641373T3
(es)
|
2012-10-02 |
2017-11-08 |
Proclara Biosciences, Inc. |
Uso de P3 de proteínas de fusión de bacteriófagos como agentes de unión amiloides
|
CN103509121B
(zh)
|
2012-11-22 |
2015-01-28 |
苏州康宁杰瑞生物科技有限公司 |
一种fsh融合蛋白及其制备方法和用途
|
WO2014093698A1
(en)
|
2012-12-12 |
2014-06-19 |
The Methodist Hospital Research Institute |
Multi-aptamer-based, cell-specific, one-step tumor cell detection assays
|
CA2899089C
(en)
|
2013-03-15 |
2021-10-26 |
Biogen Ma Inc. |
Factor ix polypeptide formulations
|
EP3003349B1
(en)
|
2013-05-28 |
2018-12-12 |
Proclara Biosciences, Inc. |
Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
|
AU2015358504A1
(en)
|
2014-12-03 |
2017-06-29 |
Proclara Biosciences, Inc. |
Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
|
CN114656573A
(zh)
|
2015-05-30 |
2022-06-24 |
分子模板公司 |
去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
|
CN108348603B
(zh)
|
2015-11-03 |
2023-12-29 |
Ambrx公司 |
抗cd3叶酸结合物和其用途
|
SG10201601719RA
(en)
|
2016-03-04 |
2017-10-30 |
Agency Science Tech & Res |
Anti-LAG-3 Antibodies
|
SG10201603721TA
(en)
|
2016-05-10 |
2017-12-28 |
Agency Science Tech & Res |
Anti-CTLA-4 Antibodies
|
IT201700084299A1
(it)
|
2017-07-24 |
2019-01-24 |
Univ Degli Studi Padova |
Peptidi derivati dal GAP24 per l’uso nel trattamento della forma X della neuropatia periferica di Charcot-Marie-Tooth
|
EP3813726A1
(en)
*
|
2018-06-27 |
2021-05-05 |
Cirlo GmbH |
Implants for recruiting and removing circulating tumor cells
|
PE20231680A1
(es)
*
|
2021-02-17 |
2023-10-19 |
Dr Falk Pharma Gmbh |
Anticuerpos anti-cd30l y usos de estos
|
WO2023173084A1
(en)
|
2022-03-11 |
2023-09-14 |
University Of Rochester |
Cyclopeptibodies and uses thereof
|